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1064-151 Outcomes of Patients Removed From a Cardiac 
Transplant Waiting List: Implications for Maximizing a 
Scarce Resource 
Katherine J. Hoercher, Patrick M. McCarthy, Eugene H. Blackstone, Michael K. Banbury, 
Nicholas G. Smedira, Jose L. Navia, James B. Young, C/eve/and C/inic Foundation, 
Cleveland, Ohio. 
Background and Purpose: The continued shortage of organ donors has mandated a goal 
of both reduction of the waiting list and limiting cardiac transplantation (Tx) to those most 
likely to achieve the greatest benefit. This study analyzes the impact of removal of 
patients (pts) from the waiting list on both mortality and identification of its determinants. 
Methods: Data was reviewed on pts listed for Tx at a single center over an eleven year 
pedod between 1989 and 2000. Review of our heart transplant database was supple- 
mented with chart analysis and telephone follow-up with pts or cardiologists. Of this 
group, 21 pts were lost to follow-up. Muitivadable analysis of time-relatad survival used 
bootstrap bagging. Results:177 pts were removed from the waiting list; 73 pts are cur- 
renUy alive and 83 died following removal. Mean follow-up is 4.2 years. The most com- 
mon reason for removal was medical improvement (55%), followed by psychosocial 
contraindicetions (16%), medically unsuitable (15%), and transfer to another Tx center 
(10%). Survival is 78%, 45%, and 25% at 1, 5, and 10 years respectively after removal. 
Survivors were largely NYHA class I (48%) or II (30%), 13 pts were relisted and 12 trans- 
planted. 8 pts underwent partial eft ventriculectomy as a surgical alternative to Tx. A his- 
tory of malignant ventricular arrhythmia was identified in 40/83 deceased pts with 
subsequent sudden death the most common known cause of mortality (19%). Overall, 
pts removed secondary to clinical improvement had the most favorable eady survival 
(89% at 1 yr), versus the medically unsuitable, who had the least favorable survival (11% 
at I yr). Conclusion: In the subset of pts delisted secondary to clinical improvement, opti- 
mization of pharmacological therapy and the use of alternative surgical therapies has 
resulted in an acceptable 1 year survival. This finding has the potential to identify pts cur- 
renUy listed for transplant who are unlikely to gain survival benefit from the procedure 
and maximizes use of limited organ resources. The results also suggest that given the 
risk for sudden death in this heart failure population, electrophysiology studies and AICD 
implantation should be considered prior to removal. 
1064-152 Clinical Risk Factors for Development of Nonlymphoma 
Cancer Poat-Heart and Heart-Lung Transplantation: 
Analysis of 30-Year Follow-Up in 1,026 Patients 
Shao-Zhou Gao. Mark G. Perlroth, Jose G. Montoya, Joan L. Miller, Sue DiMiceli, Bill 
Brown, Phillip E. Oyer, John S. Schroeder, Stanford University School of Medicine, 
Stanford, Califomia. 
Background: The use of immunosuppressive r gimens for organ transplantation (Tx) is 
associated with increased frequency of malignancy. We examined the incidence of non- 
lymphoma cancers (NLC) among heart (H) and heart-lung (H-L) Tx recipients and identi- 
fied potential predisposing factors. 
Methods: Between 1968 - 1997 1026 patients underwent H (874) or H-L (152) Tx. 122 
heart, and 7 heart-tung Tx recipients (12,6%) developed NLC. Four regimens (cohort 1- 
4)were used. 1: Pradnisone (PRED), Azathiopdne (AZA); 2: PRED, AZA, Cyclosporine 
(CyA) 3: PRED, AZA, CyA, OK'I'3, ganciclovir; 4: OKT3, ganciclovir, tacrolimus, rnyco- 
phenolata, Risk factors evaluated included age, gender, HLA, prior cardiac diagnosis, 
CMV infection, rejection, genciclovir, and calcium channel blocker use. 
Results: No correlation of NLC was found with four different regimens. Older recipient 
age, male gender, and frequency of rejection episodes correlated with NLC development. 
Those receiving ganciclovir prophylaxis, compared with all other H and H-L Tx recipients, 
had less NLC (p<0.05), Calcium channel blockers had no effect. 38 patients had 2 or 
more NLC. Actuarial frequency of NLC was 30% at 13,3 years. 
Conclusion: Modification of pest-transplantation immunosuppressive regimens did not 
alter NLC incidence. Recipient age, male gender and rejection frequency were associ- 
ated with increased NLC development. NLC prevalence reached 30% 13.3 years after 
Tx. 
1.0e ~ 
u, 
.gO Cohort 
.85 4,N 
+ 4.14-cmlS~od 
"80 "" 3.00 
~Q- .75 " 3.N-centmred 
30 a 2,00 
o 2.N-cenlmf ed
v 1.0~¢ enletH 
t4 2 4 $ | 10 12 
Years 
JACC March 6, 2002 
POSTER SESS ION 
1065 Determining Cardiovascular Risk in the 
Elderly 
Sunday, March 17, 2002, 3:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 3:00 p.m.-4:00 p.m. 
1065-141 The Morphology of Aort ic Valve Sclerosis Predicts 
Cardiovascular Disease 
Kirstan Tolstruo, Carlos A. Roldan, Michael H. Crawford, Veterans Affairs Medical 
Center, Albuquerque, New Mexico, Cedars-Sinai Medical Center, Los Angeles, 
California. 
Background: Aortic valve sclerosis (AVS) detected by transthoracic echocardiography is
associated with cardiovascular morbidity and mortality. Since it is not cost effective to test 
all patients (pts) with AVS for cardiovascular disease (CVD), the identification of paUents 
at highest dsk is important. We sought to develop a morphologic lassification of AVS by 
transesophageal echocerdiography (TEE) that may identify patients at highest risk. We 
correlated the types of AVS with CVD defined as coronary artery disease, carotid artery 
disease, or peripheral vascular disease. 
Methods: A total of 173 pts age > 50 years (mean 67 ± 9 years) underwent TEE, TEE's 
were interpreted by two experienced observers blinded to the patient's clinical data. The 
aortic valve was defined as normal (_< 2ram), mildly (2-4ram), or moderately (> 4-6ram) 
sclerotic. Valve sclerosis was classified as: Type I (localized, non-nodular), type II (local- 
ized, nodular), type III (diffuse), and type IV (mixed type). 
Results: Of the 173 pts, 72 (42%) had AVS, The morphologic distribution was: Type I, 
n=5 (7%); type II, n=7 (10%); type III, n= 23 (32%); and type IV, n=37 (51%). Of the 37 
pts with mixed AVS (type IV), 29 had mixed nodular and diffuse sclerosis. AVS in general 
was not associated with CVD. However, the 29 pts with mixed nodular and diffuse AVS 
had significantly more CVD (p=0.05), coronary artery disease (p=0.05), and history of 
CABG (p= 0.004) (OR 3, 3, and 7, respectively). Also, when compared with age, hyper- 
tension, diabetes, smoking, and hypercholesterolemia, this mixed type of AVS was the 
only independent predictor for CVD by stepwise logistic regression analysis. 
Conclusions: In patients over 50 years with aortic valve sclerosis, the finding of a mix of 
nodular and diffuse sclerosis identifies those at increased risk for cardiovascular disease. 
Thus, these patients need further evaluation. 
1065-142 Stratification of Risk for  a First Cardiovascular Event in 
the Elderly: Importance of Echocardiography 
Teresa S. Tseng, Kent R. Bailey, Marion E. Barnes, Yasuhiko Takemoto, Aaron Terry, 
Sanderson A. Cauduro. James B. Seward, Mayo Clinic, Rochester, Minnesota. 
Background: The risks for myocardial infarction (MI), need for coronary revasculariza- 
t/on procedures (CR), congestive heart failure (CHF), atrial fibrillation (AF), transient 
ischemic attack (TIA) and stroke increase with age. Primary prevention of these events 
requires accurate risk stratification. 
Methods: The study population consisted of a random sample of Olmstad County, MN 
patients aged >65 years who underwent echocardiography in 1990-98. Eligible patients 
were those in sinus rhythm, and free from a history of MI, CR, CHF, AF, TIA and stroke. 
Using Cox regression, we examined the clinical, ECG, and echocardlographic (echo) 
predictors of the composite endpoint of these aforementioned events. 
Result:;: The study included 1,297 patients (494 men; 803 women), mean age 74 + 7 
years. Newly developed events during the follow-up time of 4.5 ± 2.7 years included 93 
MI, 115 CR, 109 CHF, 109 AF, 41 TIA, and 76 strokes. The number of patients who had 
>1 event was 368 (28%), and 338 (26%) died. For prediction of the composite endpoint, 
the significant non-echo variables were age (Z2=49), hypertension (;(2=24), diabetes 
(Z2=8), and ECG left ventdcular hypertrophy (Z2=5). The echo predictors were left atrial 
volume indexed to body surface area (Z2=34), diastolic function grade (Z2=29), left ven- 
tricular mass indexed to height (X2=33), and left ventricular ejection fraction (Z2= 12), all 
P<0.05. When all 4 echo variables were considered together, each was independently 
significant, with total model Z2=79. When both non-echo and echo variables were 
entered simultaneously in a multiple Cox regression model, all but ECG left ventricular 
hypertrophy remained independently predictive of risk for the composite endpelot, model 
;(2=143. A composite clinical/echo score was dedved, based on these 7 variables, which 
yielded 9 risk groups with 5-year Kaplan-Meier event rates of 6%, 7%, 18%, 28%, 31%, 
33%, 36%, 48%, and 74%. An analogous echo score produced 7 risk groups with 5-year 
event rates of 3%, 14%, 21%, 28%, 35%, 37%, and 58%. 
Conclusion: The 5-year risk of age-related cardiac events was high in this group of eld- 
erly patients. Echocardiography was incremental to clinical data in stratification of risk for 
a first event. 
1065-143 Mycopiasma Pneumonias in Calcified Aort ic Valves 
Humberto P/err/, Mar/lie H. Santos, Maria L. Hiauchi, Marcia M. Re/s, Nadia V. 
Sambiase, Lea M. Demamhi, Jose A. Ramires, Mauricio Wanjgarten, Heart Institute 
School of Medicine, Sac Paulo, Brazil. 
Background - Calcification in stenotic aortic valves (SAO) has been considered as an 
atheroscleretic process by some authors. However this concept is controversial as many 
patients with systemic severe atherosclerosis do not present aortic stenosis. We have 
recently found Mycoplasma pneumoniae (MP) in atherosclerotic plaques. Mycoplasmas 
are the only bactada that present high content of cholesterol in their membrane. Hera we 
hypothesized that high amounts of lipids due to MP membrane accumulation are present 
in aortic valves AV favodng deposition of calcium. Methods - For detection of MP we 
used the electron microscopy and "in situ' hybridization (ISH) techniques. A quantitative 
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study was performed in ISH slides using Leica image Analysis System. Three groups AV 
were analyzed: Group A - 10 autopsy AV from non-atherosclerotic patients. Group B - 10 
autopsy non-stenotic AV of severe atherosclerotic patients. Group C - 10 stenotic AV 
from valvular replacement Results - MP was present in 100% of valves from groups A, B 
and C. MP was diagnosed at electron microscopy as extracellular irregular small struc- 
tures containing granular dots resembling DNA or RNA (confirmed by ISH), a simple 
envelope membrane, with no intracellular organelles. Group B presented higher % area 
of MP than group A (1,8 vs 0,7), that concentrated in the calcified nodules (5,5) seen at 
ISH as small brown dots. Group C had higher amount of ISH positive areas only in the 
calcified areas where the ISH revealed homogeneous taining pattern associated to the 
small dots pattern. The tissue surrounding the calficified areas was usually thickened by 
fibrosis and mononuclear inflammation, and presented significant tess amount of MP 
DNA (0,33) p<0,01. Conclusion - Mycoplasma pneumonias is a frequent bacteria in aor- 
tic valves. A greater amount is present in patients with systemic atherosclerosis, and 
mainly in calcified fool. The fibrotic calcified nodules of SAV present characteristics com- 
patible with old foci of mycoplasma accumulation. The areas of granulation tissue and 
fibrosis surrounding calcified nodules may represent an immune response against bacte- 
ria proliferation. 
1065-144 Cardiovascular Risk Factors and Mortality From the 
Seven Countries Study 40 Years After: The Greek 
Experience 
Chdstos Pitsavos, Chdstine Chrysohoou, John Skoumas, Demosthenes Panaaiotakos. 
Anastasia Katinioti, Anastasios Dontas, Christodoulos Stefanadis, Alessandro Menotti, 
PavIos Toutouzas, University of Athens, Athens, Greece, Epidemio/ogy School, 
University of Minneapolis, Minnesota. 
BACKGROUND. The Seven Countries Study has completed 40-years activity and the 
middle-aged populations tudied at the onset are presently composed of elderly subjects. 
This study aims to examine cardiovascular (CVD) dsk factors in relation to CVD mortality 
in the Corfu cohort and compare these findings with other populations, included in the 
study. 
METHODS. The population studied in this analysis consisted of rural men enrolled at 
f 960 (n=509, 49.7=5.7 years old). Among several factors the conventional CVD dsk fac- 
tors were investigated. Univariate and multivariate survival analyses were performed with 
CVD mortality as the end-point. Cox proportional hazards models were used in order to 
assess the investigated parameters and to compare survival distributions among popula- 
tions. 
RESULTS. The age adjusted 25-year death rate (per 1000) from all causes was 40.4% 
(95% CI 36.2-44.6%), while the 40-years death rate was 86.4% (95% CI 72%-98%). The 
25-years CVD mortality was 7.6% (95% 6.2-9.3%) while the 40-years was 18.2% (95% 
16.9-23.2%). Age (Hazard ratio=t.086, P<0.01), systolic blood pressure (HR=1.023, 
P<0.01), serum cholesterol (HR=1.0043, P<0.01), physical activity (HR=1.051, P<0.01 ), 
body mass index (HR=1.013, P<0.01) and smoking (HR=1.017, P<0.01) were indepen- 
dently associated with 40-year CVD mortality. The observed associations between 
depression (HR=1.007, P<0.07), afternoon siesta (HR=l.01, P<0.08), HDL-cholesterol 
(HR=I.003, P<0.07), subscapular skinfold thickness (HR=1.002, P<0.09) and mortality 
were related on the in- or exclusions of early death (P-value < 0.08). Published data from 
the other cohorts showed lower CVD mortality in the Mediterranean cohorts (Italy, 
Greece and Croatia/ Serbia) compared to the North European and US populations 
(P<0.001). 
CONCLUSION. In these eldedy men age, smoking habits, systolic blood pressure, 
serum cholesterol, body mass and physical activity, were consistently associated with 
CVD mortality. Evidences from other cohorts indicate differences in mortality between 
populations that may attribute to dietary patterns or cultural particularities that they did 
not investigated in the present study. 
1065-145 Plasma Lycopene and the Risk of Cardiovascular 
Disease in Women 
Howard D. Sesso, JuUe E. Buring, Edward P. Norkus, J Michael Gaziano, Brigham and 
Women's Hospital, Boston, Massachusetts. 
Lycopene remains sparsely tested in prospective studies for its role in the pdmary pre- 
vention of cardiovascular disease (CVD). We therefore determined whether plasma lyco- 
pens levels in middle-aged and older women from the Women's Health Study predicted 
the risk of developing CVD in a prospective, nested case-control design. Baseline bloods 
were collected from 28,263 (71%) of 39,876 women, of whom 483 cases of CVD (includ- 
ing myocardial infarction (MI), stroke, CVD death, revasculadzation procedures, and 
angina) and 483 age- and smoking-matched controls free of CVD dudng an average of 7 
years follow-up were selected. Besides plasma lycopene, other plasma carotanoids and 
total cholesterol (TC) were measured, plus baseline coronary and dietary risk factors. Of 
the 483 cases identified with CVD, there were 109 MIs, 112 strokes, 85 revasculadza- 
tions, 33 CVD deaths, and 144 cases of angina. In analyses matched on age and smok- 
ing, plus adjustment for plasma TC level, the relative risks (RRs) (95% confidence 
intervals) of total CVD for women in the lowest to highest quartiles of plasma lycopene 
were 1.00 (rsf), 0.78 (0.55-1.11), 0.56 (0.39-0.81), and 0.62 (0.43-0.90) (p, linear 
trend=0.004). Upon additional adjustment for coronary risk factors, the RRs of total CVD 
for women in the lowest to highest quartiles of plasma lycopene were 1.00 (ref), 0.94 
(0.60-1.49), 0.62 (0.39-1.00), and 0.67 (0.41-1.11) (p, linear trend=0.05). This pattern in 
RRs suggested a threshold effect in which women in the upper haft of plasma lycopene 
had a significant 34% reduction in the CVD risk. For CVD excluding angina, an L-shaped 
association was apparent as women in the upper three quartiles had a significant multi- 
variate 50% risk reduction compared with those in the lowest quartile of plasma lyco- 
pens. The addition of individual plasma carotenoids did not strongly impact the 
multivariate RRs. In conclusion, we found that higher plasma lycopene levels were asso- 
ciated with a reduced risk of CVD in middle-aged and older women. A better understand- 
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ing of the determinants of plasma lycopene levels is needed to determine how to raise 
plasma lycopene up to a clinically relevant level at which cardiovascular benefits may be 
attained. 
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1086-153 Inter-Relationship of Endothelin-1 and Natrluretic 
PepUde Secretory Responses to Acute Exercise in 
Patient With Chronic Heart Failure and Healthy Controls 
Mohammed Yousufuddin. Waqar Shamim, Marcus Flather, Mohamed Amrani, Andrew J 
S. Coats, National Heart and Lung Institue, London, United Kingdom. 
We investigated the inter-relationship between pathogenic endothelin-1 (ET-t) and 
counter-regulatory atrial (ANP) and brain (BNP) natriuretic peptides in patients with sta- 
ble CHF. Methods: Sixty-men (58+10 yr.) with stable CHF (ischaemic or idiopathic ardi- 
omyopathy only) of NYHA grade I-IV and ejection fraction <40% were enrolled. Sixteen 
age-matched (56_+6) healthy men served as controls. Venous blood samples were 
obtained at rest and peak exercise. Cardiopulmonary exercise was performed using 
modified Bruce treadmill protocol and peak oxygen consumption (VO2) was measured 
(AMIS 2000,Denmark). Investigations were performed after overnight fast. Radioimmu- 
nometric assay (Shionaria, Shionogi,Japan) were used to measure ANP and BNP and 
ELISA (Biotra, Amersham,UK) to measure ET-t. Alternating Conditional Expectation 
Algorithm was used to elucidate the relationship between peptides. Results: Resting 
plasma levels of ANP [median and (interqurtile 25-75%): 12.4 (8.0-2t.4), 4.4 (3.1-5.1) 
pmol/I, P=0.001)], BNP [14.6 (6.0-37.7), 1.15 (0.8-2.3) pmol/1, P<0.0001)], and ET-1 [2.1 
(1.6-2.9), 1.8 (1.2-1.9) pmol/], P=0.05)], were higher in patients than in controls. VO2 was 
higher in controls than in patients (35.8+5.2, 19.9-J:8.1ml/kg/min; P<0.0001). All these 
peptides were significant increased with exercise both in patients and controls (P --0.001 
to <0.0001 ). Resting or peak exercise ET-1 was correlated with resting or peak exercise 
ANP and 8NP (r=0.53 to 0.83; P=g.01to <0.0001) in patients not in controls. Logarithm 
transformed ANP and BNP (resting and peak) were linearly related to resting as well as 
peak ET-1 JR-squared 0.20 - 0.66, Slope 0.89 to 2.41(CI 0.42-1.40 to 1.94-2.88), con- 
stant 0.87 to 2.31 (CI 0.2-1.18 to 1.87-2.75); all P <0.0001). Based on regression models, 
we estimated plasma levels of natriuratic peptidec using resting ET-1 as a predictor. Dou- 
bling in resting ET-1 leads to a predictable increase in ANP (2.18-fold resting and 2.13- 
fold peak exercise) and BNP (5.32-fold resting and 4.45-fold peak exemise). Conclu- 
sions: Rise in plasma ET-I in patients not in controls is associated with predictable 
increase in not only resting but also peak exercise plasma ANP and BNP. 
1086-154 Ventilatory Response to Exercise in Heart Failure 
Patients Treated With Bats-Blockers Is a Better 
Predictor of Survival Than Peak Oxygen Consumption 
Tatiana O. Tsvetkova. Brian D. Lowes, Alastair D. Robertson, Simon F. Shakar, JoAnn 
Lindenfeld, Michael R. Bristow, Eugene E. Wolfel, University of Colorado Health 
Sciences Center, Denver, Colorado. 
Background: Abnormally high ventilatory response to exercise was shown to be a pow- 
erful and independent predictor of survival in heart failure patients not receiving beta- 
blockers. However, the prognostic value of ventilatory responses in patients chronically 
treated with beta-blockers is unknown. 
Methods: We performed a retrospective review of randomly selected charts available on 
site at University of Colorado Heart Failure Clinic. Adults with chronic heart failure due to 
ischemic and non-ischemic cardiomyopathy, who underwent cardiopulmonary exemise 
testing were included if they were on a beta-blocker in addition to standard medical treat- 
ment of hearl failure. Patients with lung disease were excluded. The abnormally high 
ventilatory response t'o exercise was defined as the value of ventilation to carbon dioxide 
(CO2) production (VENCO2) at peak exercise. Cut off values were based on 80 th percen- 
tile and higher, which corresponds to VENCO2> 44.7, as previously published as a pre- 
dictor of survival in patients not treated with beta-blockers by Robbins M. et al 
(Circulation.1999; t 00:2411-24t 7). The primary end-point was death due to any cause. 
Results: There were 51 patients eligible for analysis. 10 patients had abnormally high 
ventilatory response with mean VENCO 2 = 51.9!--5.7 compared to 41 patients with nor- 
mal ventilatory response 36.5+4.1 (p=0.005). There were no significant difference in age 
59~11 vs. 54_+10 years, LVEF 30%_+13 vs. 30%_+12, etiology 50% vs. 52% of ischemic 
cardiomyopathy, females 20% vs. 22.5 %, peak VO 2 12.1 +~2 vs. 15.6_+4.2 ml/kg/min and 
RER 1.1_+01 vs. 1.1+0.1 between two groups. Kaplan-Meier survival curves at 5 years 
demonstrated a survival rate of 47% in patients with abnormally high ventilatory 
response (VENCO2> 44.7) compared to 98% in those with normal ventilatory response 
(p=0.001). Predicted 5 years survival was 80% for patients with peak VO2 <14 ml/kg/min 
and 86% in patients with peak VO2>14 (p=0.07). 
Conclusions: Abnormally high ventilatory response is a better predictor of survival than 
peak oxygen consumption in heart failure patients treated chronically with beta-blockers. 
